Research programme: protein therapeutics - Anaphore

Drug Profile

Research programme: protein therapeutics - Anaphore

Alternative Names: Atrimer; Atrimer drug conjugates; Atrimers; ATX-3105; IL-23R - Anaphore; MBP-DC-SIGN; Trail-R - Anaphore

Latest Information Update: 03 Dec 2010

Price : $50

At a glance

  • Originator Borean Pharma
  • Developer RuiYi
  • Class Proteins
  • Mechanism of Action Apoptosis stimulants; Interleukin 23 inhibitors; TRAIL receptor 1 agonists; TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes - Autoimmune disorders; Cancer; Psoriasis

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer; Psoriasis

Most Recent Events

  • 03 Dec 2010 Preclinical development is ongoing in USA
  • 03 Dec 2010 Research programme: protein therapeutics - Anaphore is available for licensing as of 03 Dec 2010. http://www.anaphore.com
  • 16 Nov 2010 Preclinical pharmacodynamics data presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top